Kaken Pharmaceutical Co., Ltd. (TYO:4521)
3,985.00
+5.00 (0.13%)
Aug 25, 2026, 3:24 PM JST
Kaken Pharmaceutical Revenue
Kaken Pharmaceutical had revenue of 30.16B JPY in the quarter ending June 30, 2026, with 59.83% growth. This brings the company's revenue in the last twelve months to 88.16B, down -6.86% year-over-year. In the fiscal year ending March 31, 2026, Kaken Pharmaceutical had annual revenue of 76.87B, down -18.25%.
Revenue (ttm)
88.16B
Revenue Growth
-6.86%
P/S Ratio
1.71
Revenue / Employee
79.14M
Employees
1,114
Market Cap
150.72B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 76.87B | -17.16B | -18.25% |
| Mar 31, 2025 | 94.04B | 21.99B | 30.52% |
| Mar 31, 2024 | 72.04B | -940.00M | -1.29% |
| Mar 31, 2023 | 72.98B | -3.05B | -4.01% |
| Mar 31, 2022 | 76.03B | 1.06B | 1.41% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Towa Pharmaceutical | 279.94B |
| Sawai Group Holdings | 203.79B |
| Tsumura & Co. | 199.23B |
| Nippon Shinyaku | 180.29B |
| KYORIN Pharmaceutical | 125.68B |
| Mochida Pharmaceutical | 122.04B |
| Kissei Pharmaceutical | 98.60B |
| Zeria Pharmaceutical | 91.12B |
Kaken Pharmaceutical News
- 18 days ago - Kaken Pharmaceutical Quarterly report: Q1 2027 - Filings
- 18 days ago - Kaken Pharmaceutical Slides: Q1 2027 - Filings
- 3 months ago - Kaken Pharmaceutical Slides: Q4 2026 - Filings
- 3 months ago - Kaken Pharmaceutical Quarterly report: Q4 2026 - Filings
- 7 months ago - Kaken Pharmaceutical Quarterly report: Q3 2026 - Filings
- 9 months ago - Kaken Pharmaceutical initiated with a Neutral at UBS - TheFly
- 10 months ago - Kaken Pharmaceutical Quarterly report: Q2 2026 - Filings
- 10 months ago - Kaken Pharmaceutical Slides: Q2 2026 - Filings